ライフサイエンスコーパス: multimodality

1 all with the inherent advantages of the XPCI multimodality.

2 y (CT)-guided interventional procedures in a multimodality abdominal phantom.

3 The relationship between cognition and the multimodality AD biomarker was stronger in individuals w

4 We also discuss 'multimodalities' addressing postoperative nausea and vom

5 A single multimodality agent that can be used with magnetic reson

6 the first 124I-labeled photosensitizer as a "multimodality agent", which could further be improved by

7 Research supports the need for multimodality and individualized treatment programs.

8 ments are aiming to achieve high-resolution, multimodality and lifetime-based in vivo fluorescence im

9 resonance imaging in clinical practice, and multimodality and molecular imaging as new technologies.

10 future of tumor angiogenesis imaging lies in multimodality and nanoparticle-based approaches, imaging

11 New phenomena of multimodality and scaling behavior in the distribution o

12 Medical imaging with multimodality and whole-body technologies has continuous

13 ingle experiments to large multi-instrument, multimodality, and multicenter studies.

14 activation, extended imaging and theranostic multimodality, and synergistic application of multiple t

15 er chemotherapy alone (44.3 months) or after multimodality approach (47.4 months; P = .81).

16 ity in subjects with carotid plaques using a multimodality approach combining FDG positron emission t

17 tion of contrast material-enhanced US into a multimodality approach for diagnosis of HCC and its bene

18 This short but dose-intensive multimodality approach for stage IIIB breast carcinoma i

19 A multimodality approach has allowed operators to overcome

20 es were treated with curative intent using a multimodality approach involving either preoperative or

21 Accordingly, a multimodality approach is increasingly used for diagnost

22 A multimodality approach paying attention to a range of po

23 n reducing complications and deaths within a multimodality approach remains substantial and should be

24 he future of HFpEF risk assessment lies in a multimodality approach that combines the relevant echoca

25 In this study, we took a multimodality approach to evaluate the phenotypic effect

26 It is hoped that a multimodality approach, which incorporates targeted ther

27 ) to systemic treatment either alone or with multimodality approach.

28 nefit was achieved by radical surgery within multimodality approaches (HR 0.911, 95% CI 0.53-1.58; P

29 Enthusiasm for multimodality approaches for gastric lymphoma has lead t

30 squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities.

31 Multimodality approaches remain the forefront of interve

32 We further discuss opportunities provided by multimodality approaches such as PET/MRI and PET/optical

33 However, emerging multimodality approaches such as positron emission tomog

34 ts are expected to improve even further with multimodality approaches that include newer chemotherapy

35 t distant goal, attention has shifted toward multimodality approaches to cancer therapy, sometimes co

36 Multimodality approaches to colorectal imaging that inco

37 n the 1970s with the broader introduction of multimodality approaches, often including combination ch

38 ccompanied by drastic cross validation using multimodality approaches.

39 his study sought to evaluate the impact of a multimodality-appropriate use criteria decision support

40 sected nodes, 0.76; P=0.007), but not in the multimodality arm (hazard ratio 1.00; P=0.98).

41 ement may account in part for their observed multimodality, as might newly identified afferent neuron

42 This multimodality attack on the same tumor antigen may have

43 rkers were merged into a highly AD-sensitive multimodality biomarker reflecting neural integrity.

44 uld lead to development of multidisciplinary/multimodality brain amyloidosis biomarkers that are reli

45 and systemic therapy that are part of modern multimodality breast cancer treatment can replace axilla

46 designed specifically for three-dimensional multimodality breast imaging could make possible some of

47 Multimodality cardiovascular imaging plays a central rol

48 h the goal of promoting the nascent field of multimodality cardiovascular molecular imaging.

49 on tomography and cardiac magnetic resonance multimodality characterization of the acutely infarcted,

50 ess for antibody-based agents, we designed a multimodality chelation (MMC) scaffold which combined a

51 t a customized dual-labeling approach with a multimodality chelation (MMC) scaffold would minimize st

52 uding refined signal analysis techniques and multimodality comparisons.

53 The sensitivity of multimodality (computed tomography [CT], ultrasonography

54 biotic-impregnated ventricular catheters and multimodality, computerized systems allow ICP monitoring

55 es new tools for interactively reviewing the multimodality data, and current static images obtained f

56 ly, this approach may be applicable to other multimodality devices such as PET/MR.

57 Molecular imaging is a multimodality discipline for noninvasively visualizing b

58 have coalesced into a multidisciplinary and multimodality effort.

59 Multimodality evaluation of EBUS-TBNA can be successful

60 iques have unique strengths and synergies in multimodality evaluation of the patient with cognitive d

61 However, a postoperative multimodality evaluation, including a consultation with

62 However, a postoperative multimodality evaluation, including a consultation with

63 Advances in multimodality gamma-cameras (SPECT/CT), algorithms for i

64 ing physician to navigate through the set of multimodality image data is thus limited.

65 , including three-dimensional image display, multimodality image fusion, quantitative measures, and i

66 nstalled a mass spectrometer in our Advanced Multimodality Image Guided Operating (AMIGO) suite and d

67 MIP-TF mouse beta-cells were multimodality imaged in models of type 1 and type 2 diab

68 The development of novel multimodality imaging agents and techniques represents t

69 Stimuli-responsive multimodality imaging agents have broad potential in med

70 Combining multimodality imaging allows visualization and quantific

71 lishment of task forces in emerging areas of multimodality imaging and critical care cardiology.

72 Aortic Bioprosthetic Valve Dysfunction With Multimodality Imaging and Its Treatment with Anticoagula

73 s of this study suggest that future clinical multimodality imaging and therapy with VEGF(121)/rGel ma

74 We have developed a multimodality imaging approach to monitor the transformi

75 Advances in multimodality imaging are enabling more accurate localiz

76 We present and test the use of multimodality imaging as a topological tool to map the a

77 Multimodality imaging based on complementary detection p

78 having no cognitive impairment and underwent multimodality imaging between Oct 11, 2006, and Oct 5, 2

79 How multimodality imaging can be integrated in clinical mana

80 combined with CT has proven to be a valuable multimodality imaging device revealing both functional a

81 ion of intensity-modulated RT and the use of multimodality imaging for target volume and organs at ri

82 the strengths of different imaging methods, multimodality imaging has become an attractive strategy

83 The evolution of multimodality imaging has paralleled these developments.

84 ypes and to couple the use of biomarkers and multimodality imaging in early translational research st

85 Multimodality imaging is indispensable for procedural gu

86 The essence of multimodality imaging is the ability to overlay imaging

87 f the progress in epilepsy localization with multimodality imaging is to allow more effective presurg

88 erapeutic components, targeting ligands, and multimodality imaging labels into one entity, termed "na

89 tant molecular target, melanin, into a novel multimodality imaging nanoplatform.

90 particles for cell labeling in vitro and for multimodality imaging of administered cells in vivo.

91 g for 8-12 weeks and underwent intracoronary multimodality imaging of an obstructive nonculprit lesio

92 Thus, multimodality imaging of experimental systemic infection

93 Multimodality imaging of tumor-bearing mice using biolum

94 of the aorta in the trauma setting remains a multimodality imaging practice, and thus broad knowledge

95 QDs) are an attractive platform for building multimodality imaging probes, but the toxicity for typic

96 ssembly of various contrast agents to design multimodality imaging probes.

97 as stimulated growing interest in developing multimodality imaging probes.

98 Multimodality imaging provides a comprehensive evaluatio

99 Multimodality imaging reveals that iNSC delivery of the

100 The advent of multimodality imaging scanners combining PET and CT has

101 small-animal imaging, a less frequently used multimodality imaging strategy is the fusion of radionuc

102 ence after catheter ablation, and subsequent multimodality imaging studies have uncovered an inverse

103 In addition, multimodality imaging studies of dual-labeled model conj

104 igate the complementary information given in multimodality imaging studies of targeted therapeutics.

105 al indication and to independently interpret multimodality imaging studies.

106 us parts of patients' bodies, we applied our multimodality imaging system to investigate several diff

107 applications, and ongoing efforts to develop multimodality imaging systems that include DBT.

108 Multimodality imaging techniques play an integral role i

109 ation and quantitation of imaging variables, multimodality imaging technology, molecular and vascular

110 t multicentre study using novel non-invasive multimodality imaging to assess structural and inflammat

111 process, highlight the value of noninvasive multimodality imaging to assess the structural and funct

112 specific recommendations for utilization of multimodality imaging to optimize risk stratification an

113 Multimodality imaging using several reporter genes and i

114 Multimodality imaging was performed in AR42J xenografts.

115 le with ultrasound imaging, thereby enabling multimodality imaging with complementary contrast.

116 rosclerotic disease using novel non-invasive multimodality imaging) study underwent fluorodeoxyglucos

117 siderable current interest to drug delivery, multimodality imaging, and electronic devices.

118 Multimodality imaging, as represented by its greatest ex

119 eting, quantitative tumor uptake assessment, multimodality imaging, biodistribution and enhanced drug

120 a culprit lesion, followed by intracoronary multimodality imaging, including optical coherence tomog

121 in the VX2 rabbit liver tumor model by using multimodality imaging, including single-snapshot radiogr

122 Specifically, we address risk factors, multimodality imaging, pathophysiology, and novel treatm

123 comprehensive assessment with integration of multimodality imaging, testing, and clinical assessment.

124 was to test the hypothesis, with noninvasive multimodality imaging, that allogeneic mesenchymal stem

125 ase in the evaluation of cardiomyopathies is multimodality imaging, which is purported to be the effi

126 epresent a novel contrast agent platform for multimodality imaging.

127 uct (SSTR2-EGFP) for nuclear and fluorescent multimodality imaging.

128 benefit to cardiac function as determined by multimodality imaging.

129 tumor-targeted monoclonal antibody probe for multimodality imaging.

130 ed in this study, a subset of whom agreed to multimodality imaging.

131 therapy, MDSCs could be a novel component in multimodality immunotherapy targeting detrimental inflam

132 rotocol-driven neurointensive care utilizing multimodality in monitoring technology for patients with

133 Use of multimodality intelligent workstations can improve the p

134 pleurectomy-decortication (P/D) as part of a multimodality lung-sparing treatment.

135 he sole treatment modality or as part of the multimodality management of brain tumor patients.

136 To assess the role of surgery in multimodality management of GISTs, we studied postoperat

137 Despite recent advances in multimodality management the prognosis of patients with

138 monstrated the power of coupling of HTS with multimodality molecular imaging and led to identificatio

139 Multimodality molecular imaging including SPECT, PET, ca

140 Development of reporter genes for multimodality molecular imaging is highly important.

141 We used multimodality molecular imaging to track the fate of inj

142 make ORCAFluors a promising new platform for multimodality molecular imaging.

143 rm with high selectivity and sensitivity for multimodality molecular imaging.

144 such thresholds should be optimized based on multimodality monitoring and individual brain physiology

145 Correlations between mean multimodality monitoring data and change-point analyses

146 This article reviews recent advances in multimodality monitoring of patients following severe he

147 The use of multimodality monitoring of patients in the intensive ca

148 ted whether electroencephalography (EEG) and multimodality monitoring parameters may facilitate asses

149 The literature supports the use of multimodality monitoring using all of the electrophysiol

150 ous surface (scalp) EEG (sEEG) recording and multimodality monitoring, including invasive measurement

151 olism can be simultaneously explored through multimodality MR imaging and PET imaging.

152 Nanoporphyrins can be used as amplifiable multimodality nanoprobes for near-infrared fluorescence

153 Dose-intensive and time-intensive multimodality neoadjuvant therapy was successfully admin

154 uptake and either the single-modality or the multimodality neurodegenerative biomarkers.

155 highlight emerging trends such as the use of multimodality neuroimaging and the employment of 'deep l

156 Multimodality neuromonitoring plays an important role in

157 rend is for the application of the so-called multimodality neuromonitoring, which includes the use of

158 haracterize sickle cell cardiomyopathy using multimodality noninvasive cardiovascular testing and ide

159 Multimodality noninvasive imaging techniques were used t

160 l regulation can be exploited to control the multimodality of gene expression distributions in two-pr

161 gs inform the long-standing debate about the multimodality of mammalian granule cells and substantiat

162 th emphasis on the potential applications of multimodality optical and SPECT/PET systems.

163 This review provides a state-of-the-art, multimodality perspective spanning the multiple organ sy

164 The wider adoption of multimodality PET/CT imaging techniques in routine clini

165 A short but dose-intensive multimodality phase II trial was designed in an attempt

166 racortical electroencephalographic (EEG) and multimodality physiological recordings in 48 comatose su

167 ore robust than Gibbs sampling approaches to multimodality problems.

168 l treatment need to be refined and a radical multimodality protocol must be subjected to a randomized

169 re considered for enrollment in the authors' multimodality protocol.

170 e question of how best to integrate TRT into multimodality protocols.

171 apy may guide the design of more efficacious multimodality protocols.

172 Several single institution series of multimodality radiochemotherapy have shown consistently

173 emerged as attractive platforms for building multimodality radiotracers for SPECT/MRI and PET/MRI.

174 This intensive multimodality regimen has resulted in a significant impr

175 The role of OXP in multimodality regimens against EC deserves further evalu

176 Our results suggest that multimodality regimens including radical resection incre

177 is in vitro study provides evidence that our multimodality reporter construct can be used to study th

178 ggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and tre

179 ffective clinical operation of an integrated multimodality scanner setting.

180 FSM examinations presented for a prospective multimodality screening consisting of DM, WBUS, and MRI.

181 entification of novel serologic markers, and multimodality screening designs have provided hope that

182 higher-order statistical features (kurtosis, multimodality) seem much harder to acquire.

183 The purpose of this study was to develop multimodality SPECT/MRI contrast agents for sentinel lym

184 Multimodality strategies incorporating radiation or even

185 nagement is emerging as a multidisciplinary, multimodality strategy to address anemia and decrease bl

186 rwent complete resection by EPP as part of a multimodality strategy.

187 xperience is described in implementing a new multimodality stress test for accurate correlation of co

188 The proposed new multimodality stress test has the potential for simultan

189 ibility and potential effectiveness of novel multimodality stress testing.

190 in anatomic and functional image fusion from multimodality systems.

191 Among adults without known CVD, a novel multimodality testing strategy using left ventricular hy

192 Optimal sensitivity for HNE ANCA requires multimodality testing.

193 The optimization of ES multimodality therapeutic strategies has resulted from t

194 Despite the use of multimodality therapeutics, it remains the second leadin

195 vidual risk factors, use of existing and new multimodality therapies that also address adherence, and

196 significant difference between surgery-based multimodality therapies; however, the largest estimated

197 e between conventional therapy (group 1) and multimodality therapy (group 2).

198 Photodynamic and multimodality therapy also may become important componen

199 ptimal role for targeting FLT3 may depend on multimodality therapy and will likely require hematopoie

200 d on CCG-3891, which included more intensive multimodality therapy and, in some cases, autologous bon

201 Using multimodality therapy before liver transplantation for h

202 vides rationale for further investigation of multimodality therapy combining kinase inhibitors with a

203 d 1- and 5-year survival from diagnosis with multimodality therapy compared with those not treated (7

204 Multimodality therapy consisted of hepatic resection, ra

205 reatments and an increase in experience with multimodality therapy continues to increase.

206 atified analysis revealed that surgery-based multimodality therapy demonstrated an improved survival

207 2 plasma samples from 18 subjects undergoing multimodality therapy for colorectal cancer.

208 In this analysis of multimodality therapy for elderly patients with GBM, OS

209 has increased because of its use as part of multimodality therapy for high-risk early stage disease

210 arkers may allow for real-time sequencing of multimodality therapy for individual patients based on a

211 Aggressive multimodality therapy for locally unresectable primary c

212 tively observed a child exposed to intensive multimodality therapy for metastatic neuroblastoma from

213 the primary modality therapy or as part of a multimodality therapy for primary breast lymphoma is ass

214 metry with the potential for single-agent or multimodality therapy for prostate cancer.

215 it can be used to augment both targeted and multimodality therapy for sarcoma.

216 observations have led to the development of multimodality therapy for the treatment of patients with

217 ((153)Sm-EDTMP) is an effective component of multimodality therapy for the treatment of primary bone

218 We report here the results of multimodality therapy for this tumor.

219 uating EGFR and AKT in patients treated with multimodality therapy found a significant association be

220 atment sequencing allows patients to receive multimodality therapy in a manner that prioritizes early

221 ay prevent the delivery of all components of multimodality therapy in many patients.

222 ognosis and pathologic response with current multimodality therapy including an individualized surgic

223 concomitant chemotherapy usually as part of multimodality therapy including endoscopic resection and

224 Quality of life during and after multimodality therapy is considered as well as ongoing c

225 Synergistic multimodality therapy is needed for breast cancer.

226 Multimodality therapy is required for the successful man

227 Multimodality therapy may help identify patients with le

228 ectively collected to evaluate the impact of multimodality therapy on posttransplant patient survival

229 tion arm, and 484 patients were treated with multimodality therapy or palliative therapy because of c

230 ttributed to the introduction of coordinated multimodality therapy through the efforts of collaborati

231 revents clinicians from providing aggressive multimodality therapy to the most appropriate individual

232 However, multimodality therapy used with curative intent is toxic

233 l CRP levels, radical tumor resection within multimodality therapy was associated with distinctly pro

234 Surgery-based multimodality therapy was associated with improved survi

235 ation of practice patterns demonstrated that multimodality therapy was most frequently administered i

236 istory of patients treated with contemporary multimodality therapy who underwent a positive margin PD

237 ntersect and overlap, so it is probable that multimodality therapy will be necessary for this disease

238 A standardized approach of multimodality therapy with intent-to-treat by transplant

239 With current multimodality therapy, nearly 90% of children with avera

240 Despite advances in surgical technique and multimodality therapy, rates of positive circumferential

241 PURPOSE OF REVIEW: Despite advances in multimodality therapy, the overall 5-year survival rate

242 Despite advances in multimodality therapy, the prognosis for invasive esopha

243 h hepatocellular carcinoma were eligible for multimodality therapy.

244 than those treated with proctectomy alone or multimodality therapy.

245 diagnosis in most patients despite intensive multimodality therapy.

246 d cancer that is often fatal despite intense multimodality therapy.

247 g and alcohol consumption, and is treated by multimodality therapy.

248 of high-risk neuroblastoma is common despite multimodality therapy.

249 ce of R2 resections, and the frequent use of multimodality therapy.

250 cer is a heterogeneous disease that requires multimodality therapy.

251 CLC treated with surgery, chemoradiation, or multimodality therapy.

252 e-free survival (DFS) rate with conventional multimodality therapy.

253 patients with dMMR rectal cancers underwent multimodality therapy.

254 y patients, who are often unable to tolerate multimodality therapy.

255 tion as the primary modality or as part of a multimodality therapy.

256 Approximately 715 patients underwent multimodality therapy; 231 patients were included in the

257 rain, and strain rate were analyzed by using multimodality tissue tracking from cine MR imaging.

258 ctor for survival and other end points after multimodality treatment and can serve as a parameter for

259 s in treatment, particularly with regards to multimodality treatment and newer systemic therapies for

260 eting agents have been incorporated into the multimodality treatment and shown promising response rat

261 lopment of new metastatic disease after RFA, multimodality treatment approaches that include RFA shou

262 with locally advanced breast cancer require multimodality treatment combining chemotherapy (and/or h

263 r lack thereof for components of the current multimodality treatment in subgroups of patients with no

264 This aggressive multimodality treatment is complex, not only regarding s

265 up A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was no

266 , community)--appeared to influence surgical multimodality treatment patterns.

267 care in colon cancer and use of C stage for multimodality treatment planning and risk stratification

268 st be administered as part of a coordinated, multimodality treatment program.

269 Although this multimodality treatment provides higher response rates t

270 f prognostic benefit alone but, as part of a multimodality treatment regime, may result in long-term

271 spective, multicenter, single-arm trial of a multimodality treatment regimen administered within a st

272 Multimodality treatment regimens have substantially impr

273 Despite recent advances in multimodality treatment regimens, the survival for advan

274 High-dose chemotherapy and multimodality treatment seemed to improve survival proba

275 The multimodality treatment strategy included catheter-direc

276 only 54% of patients received chemotherapy; multimodality treatment was associated with improved sur

277 In the era of multimodality treatment, a more refined tool is needed t

278 atomical considerations, initial assessment, multimodality treatment, and surgical approaches for the

279 ication of multidisciplinary assessment with multimodality treatment, including surgery, radiation an

280 Despite multimodality treatment, most high-grade gliomas eventua

281 mong patients who attained a CR status after multimodality treatment.

282 ne, and an additional 32 (2%) had a CR after multimodality treatment.

283 ged with an active approach using sequential multimodality treatment.

284 nt studies have reported better results with multimodality treatment.

285 in 38 of 43 children with either surgery or multimodality treatment.

286 otherapy, may become important components of multimodality treatment.

287 ent surgery alone, and 159 patients received multimodality treatment.

288 n selected cases, personalized surgery-based multimodality treatments (MMT) have been shown to signif

289 Multimodality treatments are widely recommended, althoug

290 outcomes in Group D retinoblastoma following multimodality treatments in a national retinoblastoma re

291 After multimodality treatments initiated with IVC, 50% of salv

292 ent morbidity because closure often requires multimodality treatments over a prolonged period of time

293 The intractability of malignant gliomas to multimodality treatments plays a large part in their ext

294 foundation on which to build future phase II multimodality trials for stage I/II pancreatic cancer in

295 impression of the toxicity burden in complex multimodality trials.

296 vised analysis are labeled, and (2) 'genuine multimodality,' truly distinct solutions across replicat

297 rganizations are needed to quickly translate multimodality tumor angiogenesis imaging into multiple f

298 apy will be most effective in the context of multimodality tumor management.

299 post hoc correction were used to compare the multimodality VBD estimates.

300 of multifunctional polymers combines imaging multimodality with a biocompatible, tunable, and functio